Results 81 to 90 of about 26,095 (135)

Rivaroxaban alleviates hepatic sinusoidal obstruction syndrome in mice by modulating the gut microbiota and inhibiting the PI3K/Akt signaling pathway

Frontiers in Microbiology
IntroductionHepatic sinusoidal obstruction syndrome (HSOS) is a vascular liver disease with a high mortality rate, and treatment methods are limited. Rivaroxaban is an oral anticoagulant.
Wencheng Liu, Yanbin Cheng, Xue Han, Junlin Xia, Qingyu Wei, Bing Chang, Quansheng Li   +6 more
doaj   +1 more source

Assessing the link between rivaroxaban concentration and the onset of renal impairment in elderly patients: A retrospective observational study

Asian Journal of Medical Sciences
Background: Rivaroxaban is a widely used anticoagulant, but its impact on renal function, particularly at varying plasma concentrations, remains a critical area of investigation.
Motakatla Usha Rani , Chitra Karuppiah , Penupothu Sree Nagamani   +2 more
doaj   +1 more source

Correction to “The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis”

Portal Hypertension &Cirrhosis, EarlyView.
wiley   +1 more source

Dabigatran Concentrations in an Actively Breastfeeding Mother–Infant Dyad: Extending the Evidence for Oral Thromboprophylaxis Postpartum

American Journal of Hematology, Volume 101, Issue 7, Page 1628-1631, July 2026.
Rasmus W. Green, Aljona Saleh, Pawel Baranczewski   +2 more
wiley   +1 more source

Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up

Medicina
Background and Objectives: Rivaroxaban is a direct-acting anticoagulant used to prevent stroke in patients with atrial fibrillation. Rivaroxaban is a substrate for P-glycoprotein, which is encoded by the ABCB1 gene. Rivaroxaban is also metabolized by the
Nur Ul Ain, Niaz Ali, Abid Ullah, Shakir Ullah, Shujaat Ahmad   +4 more
doaj   +1 more source

Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case-control study. [PDF]

Ther Adv Drug Saf
Yodsurang V, Wattanathum K, Srimatimanon T, Pitinanon K, Ranti A, Siripattarachai P, Hirunpatrawong P, Rungpradubvong V, Sakamoto S, Sujarit AS.   +9 more
europepmc   +1 more source

TFPIα inhibition by andexanet alfa is partially restored by protein S and factor V-short. [PDF]

Blood Adv
Crossette-Thambiah C, Bamberg K, Laffan M, Ahnström J.   +3 more
europepmc   +1 more source

Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation. [PDF]

Clin Pharmacokinet
Lai NS, Lin CJ, Kuo CH, Peng YF, Tang SC, Huang CF, Lin SY, Lin SW.   +7 more
europepmc   +1 more source

Rivaroxaban for extended anticoagulation of pediatric venous thromboembolism. [PDF]

Transl Pediatr
Pelland-Marcotte MC, Zabeida A.
europepmc   +1 more source

Real-world bleeding risk and molecular interaction profiles of direct oral anticoagulants: a comparative study integrating clinical outcomes and <i>in silico</i> docking. [PDF]

Front Pharmacol
Onar LC, Guner E, Yilmaz I.
europepmc   +1 more source